

Date Collected: 05/09/2025

Date Received: 05/09/2025

Date Reported: 05/12/2025

Fasting: Not Given

Ordered Items: VZV IgG Immunity; Anti-Mullerian Hormone (AMH)

Date Collected: 05/09/2025

VZV IgG Immunity

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
VZV IgG <sup>01</sup>	4.24		S/CO	>0.99
VZV IgG Interpretation: <sup>01</sup>	Reactive			
Please Note: <sup>01</sup>	A reactive result is considered evidence of immunity to VZV. Reactive indicates that VZV IgG was detected consistent with previous infection and/or vaccination. The signal-to-cutoff value (S/CO) is not an antibody titer and does not equate to antibody level.			

Anti-Mullerian Hormone (AMH)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Anti-Mullerian Hormone (AMH) <sup>02</sup>	1.68	0.708 02/29/2024	ng/mL	
	For assays employing antibodies, the possibility exists for interference by heterophile antibodies in the samples. <sup>1</sup>			
	1.Kricka L. Interferences in Immunoassays - still a threat. Clin. Chem. 2000; 46: 1037-1038.			
	This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.			
	Reference Range:			
	Females 31 - 35y: 0.66 - 8.75			
	Median 3.00			
	AMH concentrations of >= 1.06 ng/mL is correlated with a better response to ovarian stimulation, produced more retrievable oocytes and higher odds of live birth according to Gleicher et al. Fertility and Sterility. 2010: 94:2824-2827. The current AMH test method correlates with the study method with a slope of 0.94.			
	Females at risk of ovarian hyperstimulation syndrome or polycystic ovarian syndrome (PCOS) may exhibit elevated serum AMH concentrations. AMH levels from PCOS patients may be 2 to 5 fold higher than age-appropriate reference interval values.			
	Granulosa cell tumors of the ovary may secrete AMH along with other tumor markers. Elevated AMH is not specific for malignancy, and the assay should not be used exclusively to diagnose or exclude an AMH-secreting ovarian tumor.			

**Disclaimer**  
The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

**Icon Legend**  
▲ Out of Reference Range ■ Critical or Alert

Leebarden, Alissa

Patient ID: 80384173  
Specimen ID: 129-139-0968-0

DOB: 09/27/1989  
Age: 35  
Sex: Female

Patient Report

Account Number: 12221995  
Ordering Physician: C SIPE



Performing Labs

01: CB - Labcorp Dublin, 6370 Wilcox Road, Dublin, OH 43016-1269 Dir: Vincent Ricchiuti, PhD  
02: ES - Esoterix Inc, 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358 Dir: Brian Poirier, MD  
For inquiries, the physician may contact Branch: 800-597-8026 Lab: 800-282-7300

Patient Details

Leebarden, Alissa  
2025 W WALTON STREET UNIT 3, CHICAGO,  
IL, 60622

Phone: 815-245-9093  
Date of Birth: 09/27/1989  
Age: 35  
Sex: Female  
Patient ID: 80384173  
Alternate Patient ID: 836751

Physician Details

C SIPE  
FCI-Chicago River North  
900 N. KINGSBURY ST., STE RW6, CHICAGO,  
IL, 60610

Phone: 312-222-8230  
Account Number: 12221995  
Physician ID:  
NPI: 1184767725

Specimen Details

Specimen ID: 129-139-0968-0  
Control ID: P8DD82924C6  
Alternate Control Number:  
P8DD82924C696F881  
Date Collected: 05/09/2025 0806 Local  
Date Received: 05/09/2025 0000 ET  
Date Entered: 05/09/2025 2029 ET  
Date Reported: 05/12/2025 1207 ET